Cam Gallagher

Cam Gallagher has more than 28 years of experience in the life science and biotech industry with a focus on corporate development, marketing, operations, and early-stage investing. Mr. Gallagher has served as a member of the Ocuphire Board since January 2019 and Chair since December 2019. He is a co-founder and board member of Zentalis Pharmaceuticals (Nasdaq: ZNTL) since December 2014. He also currently serves on the board of directors of VelosBio and SelectION. In addition to his board roles, Mr. Gallagher serves as Chief Business Officer at Immusoft and business advisor to jCyte. Prior to joining Immusoft, he was a Director and Chief Business Officer at RetroSense Therapeutics, which was acquired by Allergan in 2016. Mr. Gallagher was Managing Director of Nerveda, LLC, a life science seed fund he co-founded in June 2007. Prior to these roles, he held management positions at Oncternal, Zavante, Verus Pharma, CV Therapeutics and Dura Pharma. Mr. Gallagher holds an M.B.A. from the University of San Diego and a B.S. in Business Administration from Ohio University in 1992.